invest summari beat posit outlook ahead
import pipelin data reiter ow rate price target
share sale growth across oncolog vaccin anim health
select hospital/specialti care product well margin expans opportun
underappreci view therefor multipl expans upward earn
revis drive share higher
 takeaway support posit thesi world-wide sale
increas sale increas exclud neg impact
fx growth driven oncolog vaccin sale china
increas sale china increas
exclud neg impact fx keytruda approv fda
use combin axitinib patient advanc rcc
continu advanc develop program keytruda lynparza
lenvima anim health sale grew exclud fx sale
perform reflect higher demand companion anim product primarili
bravecto line product parasit control volum growth
livestock product particularli sale new poultri swine product
partial off-set lower rumin product sale driven distributor
purchas pattern delay movement cattl feedlot
us expect anim health sale outpac market
note cold weather flood caus cattl
stay field longer product focus feedlot
also buydown distributor partner due consolid space
look see nrdl list keytruda possibl
china year keytruda lung indic
believ keytruda still well posit even without nrdl list
 report adjust dilut ep factset
consensu higher estim narrow rais
ep guidanc translat
ep growth ex-fx factset consensu adjust financi
model report increas ep estim
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
arriv price target merck share use blend dcf
competit setback key product could materi neg impact
merck abil gener profit oper cash flow depend larg continu
profit compani key product januvia janumet keytruda gardasil/
gardasil isentress result compani depend key product event
advers affect product market product could
signific advers impact result oper cash flow event could
includ loss patent protect increas cost associ manufactur gener
over-the-count avail compani product competit product discoveri
previous unknown side effect result post-approv trial increas competit
introduct new more-effect treatment discontinu remov
market product reason event could materi advers effect
sale product
merck effort may succeed develop commerci success product
like major pharmaceut compani order remain competit merck must
continu launch new product year expect declin sale product
loss market exclus mean compani futur success depend pipelin
new product includ new product may develop collabor joint
ventur product abl obtain licens acquisit accomplish
compani commit substanti effort fund resourc research develop
dedic resourc variou collabor third parti
high rate failur inher research develop process new drug
result high risk fund invest merck research program
gener financi return risk profil compound fact research
long invest cycl bring pharmaceut compound discoveri phase
market may take decad failur occur point process includ
later process signific fund invest
merck could continu face price pressur respect product merck
could continu face price pressur global particularli matur market
manag care organ govern agenc program could neg affect
compani sale profit margin unit state includ practic manag
care group institut government purchas feder law regul
relat medicar medicaid includ medicar prescript drug improv
modern act state activ aim increas price
transpar chang healthcar system enact part healthcar reform
unit state well increas purchas power entiti negoti behalf
medicar medicaid privat sector beneficiari could result price pressur
addit larger custom may futur ask receiv higher rebat
drug certain highli competit categori compani must also compet place
formulari manag care organ exclus product formulari
lead reduc usag manag care organ
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casekeytrudapeak sale vaccin sale exceed expectationsoper margin expans exce expectationsnew pipelin opportun exceed scenario casekeytrudapeak sale vaccin sale line expectationsoper margin expans in-lin expectationsnew pipelin opportun in-lin scenario casekeytrudapeak sale vaccin sale expectationsoper margin expans expectationsnew pipelin opportun scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot growth driven oncolog vaccin china growth materi gross lower promot sell cost favor fx oper non oper reflect legal settlement gain pre-tax tax net incom attribut averag oper cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom present updat os progress next line therapi nsclc june present mainten plat chemo gbrcam mpc june data present first-lin gastric mono/combo june present rcc outcom intermediate/poor risk sarcomatoid group june date habp/vabp pneumonia june date hnscc june date small cell lung cancer june event june pneumoconjug vaccin phase estimate primari decis dose eu approv monotherapi doravirin launchjuli imipenem/cilastatin imi/rel pdufa date cuti ciai juli patent expirationaugust aqu patent expir formul septemb injectionu patent expir septemb cv outcom studi estimate primari completionseptemb delstrigopdufa date novemb primari complet date endometriosi decemb pneumoconjug vaccin phase estimate primari data first-lin ovarian combin profound data second-lin metastat castration-resist prostat bemcentinib trial cohort preliminari result selumetinib regulatori submiss accept pediatr neurofibromatosi nrdl list data readout hiv infect combin regulatori author pneumoconjug vaccin phase data studi healthi registration-en data non-muscl bladder data second-lin triple-neg breast data first-lin bladder mono/combo data first-lin msi-h colorect data neoadjuvant/adjuv first-lin triple-neg breast data first-lin triple-neg breast registration-en data second-lin cutan squamou cell data first-lin extens stage small cell lung cancer imipenem/cilastatin imi/rel phase data patent patent patent roll bla submiss ebola vaccin cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom aqeu patent expir aqjapan patent expir patent file estimate primari complet date heart failur januari pneumoconjug vaccin phase estimate primari complet februari pneumoconjug vaccin phase estimate primari complet march pneumoconjug vaccin phase estimate primari completionmay patent expir combin juli pneumoconjug vaccin phase estimate primari complet juli stay expir juli estimate primari complet chronic cough august pneumoconjug vaccin phase estimate primari complet octob estimate primari complet hiv infect combin safeti primari object decemb estimate primari complet metastat castration-resist prostat cancer decemb pneumoconjug vaccin phase estimate primari studi data first-lin renal cell cancer data second-lin nasopharyng patent expir injectioneu patent injectionjapan patent patent expir method pediatr hexaval combin vaccin patent expir method make decemb estimate primari complet date second-lin nsclc stage pediatr hexaval combin vaccin avail commerci suppli januari estimate primari complet chronic cough januari pneumoconjug vaccin phase estimate primari complet februari pneumoconjug vaccin phase ped estimate primari complet april propel estimate primari complet mcrpc estimate primari complet respiratori synctial viru may cytomegaloviru cmv vaccin phase estimate primari complet septemb docetaxel prednisonephas estimate primari complet mcrpc octob lynparzaphas estimate primari complet mcrpc novemb pneumoconjug vaccin phase estimate primari patent expir februari estimate primari complet advanc endometri cancer march biopharmaceuticalsend research phase strateg collabor option extend addit year may estimate primari complet advanc non-smal cell lung cancer juli patent expirationjuli patent expirationjuli xru patent patent patent patent patent patent patent ebola vaccin patent selumetinib patent expir novemb enzalumatidephas estimate primari complet mcrpc decemb primari complet date relaps refractori classic hodgkin patent spc patent spc expirationsourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom patent patent patent patent patent spc patent spc patent patent expir patent patent spc patent spc expirationjanuari patent expir pend decemb patent expirationjun patent expir pend septemb patent expir patent expirationfebruari patent expirationapril patent expir pend may patent expir pend june patent expirationjun patent expirationjun patent patent spc patent expirationnovemb patent patent expir pend relebactam imipenem/cilastatin patent patent spc expirationmay patent patent patent expir pend patent expir pend patent expir pend doravirin patent doravirine/lamivudine/tenofovir disoproxil fumar patent patent patent patent expir pend sourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
merck co inc global healthcar compani deliv innov health solut prescript medicin vaccin
biolog therapi anim health product compani oper includ four oper segment anim health
allianc segment segment includ human health pharmaceut vaccin product
health pharmaceut product consist therapeut prevent agent gener sold prescript treatment
human disord anim health segment discov develop manufactur market anim health product includ vaccin
compani segment provid servic solut focu engag health analyt clinic servic
improv valu care deliv patient compani incorpor new jersey
